AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02880124 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Expired gas sampling
Description: Subjects will be asked, twice, to provide a forced expiration into a 10 mL plastic tube in order to collect a sample expired gases. This procedure will be done immediately before blood sampling and ingestion of the solution, every 30 minutes.
Study NCT02880124 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Indirect respiratory calorimetry
Description: A mouthpiece and nose plug will be placed on the subject and expired gases will be analyzed by a metabolic cart during 3 minutes. This procedure will be done immediately before expired gas collection, blood sampling and ingestion of the solution, every 30 minutes.
Study NCT02880124 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Indirect respiratory calorimetry
Description: A mouthpiece and nose plug will be placed on the subject and expired gases will be analyzed by a metabolic cart during 3 minutes. This procedure will be done immediately before expired gas collection, blood sampling and ingestion of the solution, every 30 minutes.
Study NCT02880124 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Indirect respiratory calorimetry
Description: A mouthpiece and nose plug will be placed on the subject and expired gases will be analyzed by a metabolic cart during 3 minutes. This procedure will be done immediately before expired gas collection, blood sampling and ingestion of the solution, every 30 minutes.
Study NCT02880124 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Palatability
Description: Subjects will be asked to fill out a short form on the palatability of the solution ingestion, after ingesting the first solution and at the end of exercise, after ingestion the last solution.
Study NCT02880124 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palatability
Description: Subjects will be asked to fill out a short form on the palatability of the solution ingestion, after ingesting the first solution and at the end of exercise, after ingestion the last solution.
Study NCT02880124 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Palatability
Description: Subjects will be asked to fill out a short form on the palatability of the solution ingestion, after ingesting the first solution and at the end of exercise, after ingestion the last solution.
Study NCT02880124 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gastrointestinal
Description: At the end of the time trial, subjects will be asked to fill out a short form on gastrointestinal issues they might have had during experimentation.
Study NCT02880124 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gastrointestinal
Description: At the end of the time trial, subjects will be asked to fill out a short form on gastrointestinal issues they might have had during experimentation.
Study NCT02880124 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Gastrointestinal
Description: At the end of the time trial, subjects will be asked to fill out a short form on gastrointestinal issues they might have had during experimentation.
Study NCT02880124 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood sampling
Description: A catheter will be inserted in an antecubital vein and a saline solution will be continuously perfused to maintain the vessel open. 15 mL of blood will be collected every 30 minutes, immediately before ingesting the solution.
Study NCT02880124 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: A catheter will be inserted in an antecubital vein and a saline solution will be continuously perfused to maintain the vessel open. 15 mL of blood will be collected every 30 minutes, immediately before ingesting the solution.
Study NCT02880124 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Blood sampling
Description: A catheter will be inserted in an antecubital vein and a saline solution will be continuously perfused to maintain the vessel open. 15 mL of blood will be collected every 30 minutes, immediately before ingesting the solution.
Study NCT02880124 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Time trial
Description: Subjects will be required to complete a simulated 20-km time trial on the cycle ergometer set in linear mode (where resistance is proportional to pedalling cadence), starting at 70% of the peak power output for the cadence spontaneously adopted by the subject during 2 hours of exercise.
Study NCT02880124 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time trial
Description: Subjects will be required to complete a simulated 20-km time trial on the cycle ergometer set in linear mode (where resistance is proportional to pedalling cadence), starting at 70% of the peak power output for the cadence spontaneously adopted by the subject during 2 hours of exercise.
Study NCT02880124 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Time trial
Description: Subjects will be required to complete a simulated 20-km time trial on the cycle ergometer set in linear mode (where resistance is proportional to pedalling cadence), starting at 70% of the peak power output for the cadence spontaneously adopted by the subject during 2 hours of exercise.
Study NCT00816153 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PVI-guided fluid management
Description: Peroperative comparison of standard care with PVI-guided fluid management (optimization of the PVI value with fluid loading)
Study NCT03822377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor orodispersible tablets
Description: Ticagrelor loading dose (180 mg) given as two orodispersible tablets (each of 90 mg), to be dispersed in saliva.
Study NCT03822377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor standard tablets
Description: Ticagrelor loading dose (180 mg) given as two standard coated tablets (each of 90 mg) to be swallowed with water.
Study NCT03456635 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: guided antimicrobial prophylaxis
Description: During the intervention period, antimicrobial prophylaxis decisions will be guided by a computerized program
Study NCT01012596 — intervention group
Intervention type: BEHAVIORAL
Intervention: Creighton Model System of Natural Family Planning
Description: Participants will learn the Creighton Model, a standardized method of natural family planning, from FertilityCare Practitioners from established FertilityCare Centers. The learning can be done in-person or long distance.
Study NCT04882748 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ADAMO
Description: Physical therapy provided with or without the help of a robot
Study NCT04882748 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ADAMO
Description: Physical therapy provided with or without the help of a robot
Study NCT00621946 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Matching Escitalopram
Study NCT00621946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Active Escitalopram
Study NCT00557349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: 40mg dose administered as a suspension or capsule as physician directs daily at bedtime for 14 weeks beginning day of hospital discharge following gastric bypass surgery.
Study NCT00557349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Famotidine
Description: 40mg dose administered as a suspension or capsule as physician directs daily at bedtime for 14 weeks beginning day of hospital discharge following gastric bypass surgery.
Study NCT00721825 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neuroaid
Description: Neuroaid capsules, 4 capsules, three times per day, during one month
Study NCT00721825 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Neuroaid matched Placebo
Description: Neuroaid matched placebo 4 capsules three times per day during one month
Study NCT04017637 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Static resistance training including two arm and two leg movements will be performed twice per week for 12 weeks.
Study NCT01462825 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: tomato ketchup meal
Description: A single intake of 200 g tomato ketchup together with 200 g white cooked rice.
Study NCT01462825 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo meal
Description: Self-prepared vinaigrette matching the qualitative and quantitative macronutrient composition of the tomato ketchup together with 200 g cooked rice resulting in a meal that is isocaloric to the tomato-ketchup meal
Study NCT01811823 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Trivalent Inactivated Influenza Vaccine
Description: The study vaccine will be the seasonal 2013 un-adjuvanted TIV which is provided as a 0•5 milliliter suspension of split virus mixture of 15 micrograms each of circulating H1N1- like strain, H3N2- like strain and B - like strain.~The WHO recommended vaccine formulation for Southern Hemisphere 2013 Influenza Season contains the following influenza strains:~* A/California/7/2009 (H1N1)pdm-like virus~* A/Victoria/361/2011 (H3N2)-like virus~* B/Wisconsin/1/2010-like virus. (Yamagata lineage)
Study NCT02722759 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: hemoglobin measurement
Study NCT03198416 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-resolution pharyngeal manometry catheter
Description: The system is a widely-used tool in gastrointestinal medicine for high resolution mapping of pressures within tubular organs.The device will be deployed trans-nasally into the pharyngeal and esophageal lumen in exactly the same fashion as is done for motility studies.
Study NCT01211223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of Metronidazole plus Amoxicillin
Description: Metronidazole plus Amoxicillin after, during and after root planning
Study NCT01229527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Patient receive a bolus of Remifentanil (0,5 mcg/Kg) before the procedure and the PCSA pump is set to inject further bolus doses of 0,5 mcg/Kg every time the patient presses its button.
Study NCT01229527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Patient receive a bolus of Remifentanil (0,8 mcg/Kg) before the procedure and the PCSA pump is set to inject further bolus doses of 0,8 mcg/Kg every time the patient presses its button.
Study NCT01229527 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meperidine
Description: Patient receive a bolus of Meperidine (0,7 mg/Kg) before the procedure and the PCSA pump with saline (sham PCSA) is connected.
Study NCT04387422 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental hyperglycemia
Description: Experimental hyperglycemia with MRI
Study NCT03202537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexlansoprazole
Description: dexlansoprazole treatment for Gastroesophageal Reflux symptoms
Study NCT01498705 — intervention group
Intervention type: OTHER
Intervention: Procalcitonin level
Description: PCT level upon admission and on days 1, 3, and 5 following baseline level
Study NCT03670199 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary advice
Description: Nutritional status assessment Explanation of standard nutritional advices with an written explanation sheet
Study NCT03670199 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapist intervention
Description: Respiratory capacity Functional capacity
Study NCT03670199 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Nutritional status assessment Presentation of the Nutrimus booklet by the coordinating dietitian Establishment or adaptation of a nutritional support (prescription of nutritional supplements if necessary). Delivery and explanation of the preoperative nutritional counseling support
Study NCT03218319 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Renin measurement
Description: patients will have a blood sample for measuring renin activity
Study NCT02380495 — intervention group
Intervention type: OTHER
Intervention: Data Collection
Study NCT03332628 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Microneedle patch
Description: Each patch contains 50 microneedles.
Study NCT03546010 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuropsychological tests
Description: WISC test, BRIEF test, NEPSY-2 test, TAP2.3 test, Teach test
Study NCT03546010 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oculometric tests
Description: When the subject see a peripheric target, he should take a look not at the target but in the controlateral half-field, at a mirror position. This is called an anti-saccade task.
Study NCT01821209 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placement of sling
Description: Placement of a retropubic urethral sling will involve dissection and harvesting of the right and left vas deferens, which we will be taken out of the body by the bed side assistant who will suture the two vas deferens together in a side to side fashion with the smaller of the two vas deferens placed in the middle of the larger one. A single 3-0 V-lock suture on a CV23 needle will be placed through one end of the vas sling and then passed into the body by the bed side assistant. The sling will then be placed on the rectum below the site of the vesicourethral anastamosis and the anastamosis will be completed. The sling will then be placed around the vesicourethral anastomosis, suspended to the pubic symphysis and tensioned to allow elevation of the vesicourethral anastomosis.
Study NCT00784550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium Bromide
Description: Long-acting muscarinic antagonist
Study NCT00784550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate/Salmeterol
Description: Inhaled corticosteroid plus long-acting bronchodilator
Study NCT03926390 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bovine colostrum
Description: bovine colostrum for first 2 weeks
Study NCT01637766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan (intra-arterial infusion)
Description: Patients will undergo a minimally invasive procedure called spinal angiography. This procedure will identify the arteries feeding the tumor causing cord compression and will determine whether chemotherapy can be safely infused.~The chemotherapy will be infused via a tiny soft plastic tube (called microcatheter) at the tumor site over approximately 30 minutes.~The drug of choice is melphalan (trade name Alkeran) at a maximum dose of 16mg/m2, adjusted for white cell count, platelet count and renal function.~We will perform up to three intra-arterial chemotherapy treatments in 3-6 week intervals, based on the results of complete blood counts.
Study NCT00648934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate Sprinkle Capsules 25 mg
Description: 25mg, single dose fed
Study NCT00648934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topamax® Sprinkle Capsules 25 mg
Description: 25mg, single dose fed
Study NCT02865590 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sinus lift with Lyophilized Equine Bone Allograft (Bio-gen , Bioteck s.p.a., Arcugnano (VI) - Italy)
Study NCT02865590 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sinus lift with deproteinized bovine bone allograft (Endobon Xenograft Granules, Zimmer Biomet, San Donato Milanese (MI) - Italy)
Study NCT02387775 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esophageal temperature control
Description: Insertion of the Esophageal Cooling Device (ECD) will take place as described in the product monograph. The ECD will be connected to the heat exchange unit Blanketrol Hyper-Hypothermia System® (Cincinnati Sub-Zero, Cincinnati, OH) and will be used for temperature control for a total of 36 hours. A patient target of 35°C will be set on the heat exchange unit. Once target is attained, it will be maintained for 24 hours. Slow rewarming will then be achieved by increasing the input target by 0.2°C per hour, until a target of 36.6°C is reached.~All temperature data (device, input target, and patient bladder temperature) will be captured automatically using Data Export Software® (Cincinnati Sub-Zero, Cincinnati, OH) on an external laptop connected to the external heat exchange unit.
Study NCT02466217 — intervention group
Intervention type: OTHER
Intervention: 1: AID groups
Description: Clinical and Biological investigations
Study NCT02466217 — intervention group
Intervention type: OTHER
Intervention: 2: Control groups
Description: Clinical and Biological investigations
Study NCT00779532 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Capsules containing 400 mg moxifloxacin, on Day 14 only
Study NCT00779532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOMAC-E2 (Org 10486-0 + Org 2317)
Description: Tablets containing 2.5 mg NOMAC and 1.5 mg E2, once daily dosing, orally taken. Daily dose either NOMAC-E2 2.5/1.5 mg or 12.5/7.5 mg.
Study NCT00779532 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin placebo
Description: Moxifloxacin-placebo capsule taken orally, Day -1 and Day 14 only
Study NCT00779532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin placebo
Description: Moxifloxacin-placebo capsule taken orally, Day -1 and Day 14 only
Study NCT00779532 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin placebo
Description: Moxifloxacin-placebo capsule taken orally, Day -1 and Day 14 only
Study NCT00779532 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NOMAC-E2 placebo
Description: Tablets containing NOMAC-E2 placebo, once daily dosing, orally taken.
Study NCT00779532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOMAC-E2 placebo
Description: Tablets containing NOMAC-E2 placebo, once daily dosing, orally taken.
Study NCT00779532 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NOMAC-E2 placebo
Description: Tablets containing NOMAC-E2 placebo, once daily dosing, orally taken.
Study NCT02895646 — intervention group
Intervention type: OTHER
Intervention: Collection of blood sample
Study NCT03703908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCX140-B
Description: Orally administered tablet
Study NCT01789580 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gambling moderator
Study NCT03309696 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham tDCS and sham rTMS
Description: Both combinations of tDCS and rTMS in this intervention are sham.
Study NCT03309696 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham tDCS and active rTMS
Description: tDCS in this intervention is sham and rTMS is active
Study NCT03309696 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active tDCS and active rTMS
Description: Both combinations of tDCS and rTMS in this intervention are active
Study NCT06452745 — intervention group
Intervention type: PROCEDURE
Intervention: Colonoscopy
Description: Colonoscopy performed as a regular practice during colorectal cancer screening.
Study NCT06452745 — intervention group
Intervention type: OTHER
Intervention: Urine and FOBT collection
Description: After patients agreement, urine and FOBT are collected before the colonoscopy and before the diet preparation of the colon.
Study NCT03670199 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensify physiotherapist intervention
Description: Respiratory capacity Functional capacity Tips adapted for physical activity and strengthening or maintenance of muscle mass Presentation of respiratory physiotherapy exercises to prevent postoperative bronchial congestion Nutrition and physical mobilization tips with the Nutrimus booklet
Study NCT03209297 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TMD treatment: physiotherapy and/or occlusal splints
Description: The patient will receive the most appropriate TMD treatment, based on current literature.
Study NCT03945851 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fMRI
Description: All subjects will undergo 2 fMRI sessions. Each of these sessions will span two days, and subjects will spend 15 minutes in the MRI each day. fMRI tasks will consist of subjects grasping and releasing a handgrip. The control arm subjects will be offered a third fMRI session after unblinding and therapy with activation of the VNS.
Study NCT03945851 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fMRI
Description: All subjects will undergo 2 fMRI sessions. Each of these sessions will span two days, and subjects will spend 15 minutes in the MRI each day. fMRI tasks will consist of subjects grasping and releasing a handgrip. The control arm subjects will be offered a third fMRI session after unblinding and therapy with activation of the VNS.
Study NCT00926302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam (Lotus Pharmaceutical Co.,Ltd.)
Description: Levetiracetam 500mg/tablet Oral once
Study NCT00926302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Keppra (Levetiracetam - USB SA Pharma Sector)
Description: Levetiracetam 500mg/tablet oral once
Study NCT04151771 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-load blood flow restriction training
Description: The intervention group will perform the exercises of the lower limbs using LL-BFRT with an occlusion pressure of 70% of arterial occlusion pressure with low training loads (30% of the 1 repetition maximum).